Skip to main content

Table 4 Comparison of shoulder ratings before and 3 months after ESWT/sham treatment in the study and placebo groups

From: Short-term outcomes of extracorporeal shock wave therapy for the treatment of chronic non-calcific tendinopathy of the supraspinatus: a double-blind, randomized, placebo-controlled trial

CMS ESWT PLACEBO P value1
PAIN    
Baseline 2.72 ± 2.61 (0-5) 3.33 ± 2.5 (0-5) 0.592
3 months 10.9 ± 4.37 (5-15) 6.11 ± 4.86 (0-15) 0.039
P value2 0.004 0.096  
ADL    
Baseline 10.27 ± 3.28 (5-18) 11.55 ± 4.21 (6-18) 0.378
3 months 17 ± 4.22 (8-20) 12 ± 5.63 (4-20) 0.059
P value2 0.005 0.779  
ROM    
Baseline 16.18 ± 4.68 (10-24) 16.67 ± 8.36 (2-26) 0.878
3 months 30.9 ± 9.05 (16-40) 18.22 ± 10.50 (6-36) 0.012
P value2 0.005 0.635  
POWER    
Baseline 13.27 ± 5.40 (5-20) 10.11 ± 3.18 (5-15) 0.170
3 months 15.27 ± 6 (6-23) 11.67 ± 3.46 (6-16) 0.170
P value2 0.096 0.119  
TOTAL    
Baseline 42.45 ± 9.83 (29-61) 41.67 ± 12.53 (20-57) 0.970
3 months 74.09 ± 20.56 (39-98) 48 ± 22.3 (17-79) 0.023
P value2 0.003 0.260  
  1. The values are given as mean ± standard deviation (range).
  2. 1 Comparison between treatment and control group both before and after treatment (Mann-Whitney U- test).
  3. 2 Comparison between before and after treatment within each group (Wilcoxon test).
  4. ESWT, indicates extracorporeal shock wave therapy; ADL, activity of daily living; ROM, range of motion; CMS, Constant and Murley Score.